Of the 12 million people who inject drugs worldwide, 13% are chronically infected with Human Immunodeficiency Virus (HIV), i.e., they live with HIV. Chronic opioid use affects the host immune system and increases an individual’s susceptibility to HIV infection. However, it is unclear how opioid use changes the course of HIV pathogenesis. Particularly, there is a gap in understanding how opioids impact HIV latency. Latency results in a reservoir of infected quiescent cells that evade antiviral immune responses, are not targeted by antiretroviral therapy (ART), and allow HIV viremia to rebound upon treatment interruption. While in vitro studies show that opioids modulate the activity of transcription factors involved in T-cell activation and HIV transcription, few studies have investigated whether opioid use impacts HIV latency in vivo in HIV-infected people. In this research, peripheral blood mononuclear cells (PBMCs) were utilized from People with HIV (PWH) with or without recent opioid use or opioid use disorder (OUD) who were enrolled in the Linking Infection and Narcology Care-Part II (LINC-II) and Studying Partial Agonists for Ethanol and Tobacco Elimination in Russians with HIV (St PETER HIV ARCH) studies conducted in St. Petersburg, Russia. Intact proviral DNA digital droplet PCR (ddPCR) assays were performed on PBMCs from antiretroviral treated PWH, with (n=8) or without (n=11) current OUD, to quantify intact and defective proviral genomes. Samples from ART-treated PWH with OUD compared to those without OUD had similar levels of intact and defective proviruses. To evaluate latency reversal, PBMCs from ART-treated PWH with or without OUD, were activated with anti-CD3/28 beads and RT-ddPCR assays were performed to measure HIV LTR-gag RNA. A variable response in PWH without OUD was seen where half of the samples showed an increase in HIV RNA upon activation. Interestingly, only 1 of 8 samples from PWH with OUD showed an increase in HIV transcription. However, no suppression of HIV reactivation was found in vitro from latent cells generated using a primary CD4+ T-cell latency model in the presence or absence of morphine. Similarly, no differences in HIV integration and transcription in vitro were observed between morphine and control conditions. Additionally, expression of opioid receptors was not detected in primary PBMCs, CD4 T cells, or macrophages. These results show that PWH with OUD have a pool of persistent HIV proviruses that are refractive to reactivation, although opioids did not affect HIV replication and latency reactivation in vitro. The discrepancy in these in vitro and in vivo results and the lack of expression of opioid receptors in immune cells suggests that while opioids do not directly impact HIV replication, latency, and reactivation in target CD4+ cells, opioids could indirectly shape the HIV reservoir in vivo by modulating general immune functions, neuroderived factors or other cells that are responsive to opioids. Eradication of the latent HIV reservoir is necessary to achieve a cure for HIV/AIDS. One approach for latency eradication is the “shock and kill” approach that entails stimulating viral production with latency-reversing agents followed by the killing of cells actively producing the virus by immune clearance. However, this approach does not induce all intact proviruses, leaving a residual reservoir. An alternative approach is to permanently repress HIV expression precluding viral rebound after ART discontinuation. Here, a nuclease-deficient disabled Cas9 (dCas9) coupled with a transcriptional repressor domain derived from Kruppel-associated box (KRAB) was used to epigenetically silence the proviral DNA. I show that specific guide RNAs (gRNAs) and dCas9-KRAB repress HIV-1 transcription and reactivation of latent HIV-1 provirus. This repression is correlated with chromatin changes, including decreased H3 histone acetylation and increased histone H3 lysine 9 trimethylation, which are histone marks that are associated with transcriptional repression. dCas9-KRAB-mediated inhibition of HIV-1 transcription suggests that CRISPR can be engineered as a tool for block-and-lock strategies. The research presented here provides evidence of opioid-mediated modulation of HIV-1 latency reactivation in PWH with opioid dependency. Additionally, we show that HIV-1 reactivation can be suppressed by epigenetic remodeling of the HIV-1 promoter using a repurposed CRISPR/Cas9 system.

Determination of bio-material by using enzyme, fluorophore or metal-nanoparticles as markers is very important. Generally, gold-nanoparticles have been used frequently as marker for increasing the sensitivity in bio-chemical assay. In this research, gold-nanoparticles were used as marker for immunoassay, DNA sequence assay, and protein analysis. However, the size of gold-nanoparticles affects directly the results of electrochemical detection. For improving the sensitivity of electrochemical method, enlargement of gold-nanoparticles was used in this study. By electroless deposition, Au will be deposited on the surface of gold-nanoparticles. The electrochemical response will thus be increased substantially. In immunoassay and DNA sequence assay, traditional 96-wells microtiter plate was used for immobilizing antibody or oligonucleotide, and the gold-nanoparticles were marked subsequently base on the immunoreaction or protein reaction of streptavidin and biotin. After gold-nanoparticles were enlarged, they were dissolved and transferred to an electrochemical cell for square wave stripping voltammetry¡]SWSV¡^analysis. Under optimal experimental condition, dynamic range of 1 ~ 500 pg/mL and 0.52 ~ 1300 aM were found respectively for RIgG and Target DNA analysis, and a good linear relationship¡]R2 = 0.9975 and 0.9982¡^. The relative standard deviation¡]R.S.D.¡^ of blank were 2.8 % and 2.4 %¡]n = 11¡^for immunoassay and DNA assay, respectively. And the variance was 2.4 %¡]n = 9¡^and 2.4 %¡]n = 12¡^for immunoassay and DNA assay, respectively. The detection limit¡]based on S/N = 3¡^of RIgG and DNA were 0.25 pg/mL and 0.52 aM, respectively. They are very competitive compared with similar results reported in the literature. Additional, a gold nanoelectrode ensemble¡]GNEE¡^coupled microchip system was developed for bio-electrochemical analysis. Due to the difference in mobility of urea and urease were mixed and allowed the enzymatic reaction to proceed in microchannel. The enzymatic product NH4+ was determined by the coupled GNEE at the outlet of the channel. Another experiment of streptavidin conjugated gold-nanoparticles¡]streptavidin-Au¡^, reductant and gold-ion¡]Au3+¡^solution was be applied here, too. The product, NH4+ or Au3+ was passed through downstream of microchannel and detected by GNEE of electrochemical system. Satisfactory linear relationship¡]R2 = 0.9778 and 0.9657¡^were found from 0.1 mM to 50 mM for NH4+ and urea in the range of 0.02 mM to 5.0 mM, respectively. The other satisfactory linear relationship¡]R2 = 0.9842 and 0.9507¡^ were found between 3.75 mg/mL and 3.75 g/mL for Au3+ and streptavidin-Au in the range of 0.2 ng/mL to 100 ng/mL, respectively. Variances of 2.5 %¡]n = 6¡^was found for analysis of with the microchip system.